1. Home
  2. CRAI vs MESO Comparison

CRAI vs MESO Comparison

Compare CRAI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRAI
  • MESO
  • Stock Information
  • Founded
  • CRAI 1965
  • MESO 2004
  • Country
  • CRAI United States
  • MESO Australia
  • Employees
  • CRAI N/A
  • MESO N/A
  • Industry
  • CRAI Other Consumer Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CRAI Consumer Discretionary
  • MESO Health Care
  • Exchange
  • CRAI Nasdaq
  • MESO Nasdaq
  • Market Cap
  • CRAI 1.2B
  • MESO 1.3B
  • IPO Year
  • CRAI 1998
  • MESO N/A
  • Fundamental
  • Price
  • CRAI $170.16
  • MESO $15.17
  • Analyst Decision
  • CRAI Buy
  • MESO Buy
  • Analyst Count
  • CRAI 1
  • MESO 4
  • Target Price
  • CRAI $228.00
  • MESO $18.00
  • AVG Volume (30 Days)
  • CRAI 118.7K
  • MESO 314.4K
  • Earning Date
  • CRAI 07-31-2025
  • MESO 08-28-2025
  • Dividend Yield
  • CRAI 1.15%
  • MESO N/A
  • EPS Growth
  • CRAI 44.21
  • MESO N/A
  • EPS
  • CRAI 8.27
  • MESO N/A
  • Revenue
  • CRAI $712,913,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • CRAI $7.47
  • MESO $177.23
  • Revenue Next Year
  • CRAI $4.48
  • MESO $314.04
  • P/E Ratio
  • CRAI $20.59
  • MESO N/A
  • Revenue Growth
  • CRAI 9.28
  • MESO N/A
  • 52 Week Low
  • CRAI $133.54
  • MESO $5.78
  • 52 Week High
  • CRAI $214.01
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • CRAI 34.65
  • MESO 60.94
  • Support Level
  • CRAI $167.82
  • MESO $14.45
  • Resistance Level
  • CRAI $183.61
  • MESO $16.23
  • Average True Range (ATR)
  • CRAI 6.65
  • MESO 0.57
  • MACD
  • CRAI -1.17
  • MESO 0.10
  • Stochastic Oscillator
  • CRAI 6.74
  • MESO 63.12

About CRAI CRA International Inc.

CRA International Inc is a U.S.-based advisory firm that provides economic, financial, and management consultancy services. The company advises clients on economic and financial issues relating to litigation and regulatory proceedings and helps businesses set important business strategies and solve performance-related issues. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. CRA International generates majority of its revenue from the United States, while it also has its presence in United Kingdom and Other Countries.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: